Each tablet contains: 0.25/0.5 mg Cabergoline
For the treatment of hyperprolactinaemic disorders, either idiopathic or due to pituitary adenomas.
For the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons
For initiation of therapy is 0.25 mg twice a week
Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level
Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease
Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level.